Hepatitis C virus (HCV) infection is a global public health problem affecting millions of people worldwide. Chronic HCV infection causes long term complications as liver cirrhosis and and its consequences as hepatocellular carcinoma. The inadequate and improperly tolerated treatment options contributed to the health burden of chronic HCV. Newer Treatments therapies had evolved that implied direct-acting antivirals (DAAs) that targeted different hepatitis C virus genomic sites. DAAs demonstrated better efficacy, patient compliance and tolerance than former antiviral therapy. transient elastography is established as noninvasive method for assessing hepatic fibrosis in HCV patients. Aim of the study: to demonstrate effectiveness of DAAs (sofosbuvir based therapy) in treating chronic HCV infection and improving hepatic fibrosis through assessment using TE. Relevant articles were identified by searching PubMed and Google scholar databases. Conclusions: This literature review revealed significant improvement in hepatic fibrosis assessed by TE in HCV patients treated by sofosbuvir based antiviral therapy.